Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AADI Aadi Bioscience	$1.65	$1.86	$1.21 ▼ $3.81	$40.75M	0.68	261,100 shs	48,668 shs
CALC CalciMedica	$2.78 -0.4%	$2.46	$1.42 ▼ $5.97	$38.98M	1.33	50,781 shs	20,844 shs
GLYC GlycoMimetics	$0.16 -6.6%	$13.48	$14.06 ▼ $63.00	$10.00M	1.62	67,672 shs	1.05 million shs
RANI Rani Therapeutics	$0.62 +13.8%	$0.53	$0.39 ▼ $3.75	$39.43M	-0.02	779,726 shs	1.11 million shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AADI Aadi Bioscience	0.00%	+1.85%	-10.81%	-6.25%	+6.45%
CALC CalciMedica	-0.36%	-4.47%	-33.81%	+54.44%	-28.72%
GLYC GlycoMimetics	0.00%	0.00%	0.00%	-99.37%	-99.16%
RANI Rani Therapeutics	+13.82%	+13.53%	+37.23%	+1.23%	-78.54%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AADI Aadi Bioscience	0.4657 of 5 stars	1.0	0.0	0.0	0.0	0.0	2.5	1.3
CALC CalciMedica	3.495 of 5 stars	3.5	5.0	0.0	0.0	2.6	3.3	0.0
GLYC GlycoMimetics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
RANI Rani Therapeutics	2.7193 of 5 stars	3.5	5.0	0.0	0.0	0.0	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AADI Aadi Bioscience	2.00	Hold	$1.75	6.06% Upside
CALC CalciMedica	3.00	Buy	$16.00	475.54% Upside
GLYC GlycoMimetics	3.00	Buy	N/A	N/A
RANI Rani Therapeutics	3.00	Buy	$7.33	1,074.46% Upside

Current Analyst Ratings Breakdown

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AADI Aadi Bioscience	$25.07M	1.63	N/A	N/A	$4.29 per share	0.38
CALC CalciMedica	N/A	N/A	N/A	N/A	$0.44 per share	N/A
GLYC GlycoMimetics	$10K	1,000.25	N/A	N/A	$0.08 per share	1.94
RANI Rani Therapeutics	$1.03M	43.57	N/A	N/A	($0.13) per share	-4.80

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AADI Aadi Bioscience	-$65.76M	-$2.35	N/A	N/A	N/A	-246.06%	-71.87%	-57.28%	11/4/2025 (Estimated)
CALC CalciMedica	-$13.70M	-$1.60	N/A	N/A	N/A	N/A	-206.51%	-103.81%	N/A
GLYC GlycoMimetics	-$37.88M	-$0.46	N/A	N/A	N/A	N/A	-230.74%	-177.39%	N/A
RANI Rani Therapeutics	-$30.02M	-$0.91	N/A	N/A	N/A	N/A	-1,258.76%	-97.97%	N/A

Latest GLYC, AADI, RANI, and CALC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/12/2025	Q2 2025	CALC CalciMedica	-$0.40	-$0.40	N/A	-$0.40	N/A	N/A
8/7/2025	Q2 2025	RANI Rani Therapeutics	-$0.19	-$0.18	+$0.01	-$0.18	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AADI Aadi Bioscience	N/A	N/A	N/A	N/A	N/A
CALC CalciMedica	N/A	N/A	N/A	N/A	N/A
GLYC GlycoMimetics	N/A	N/A	N/A	N/A	N/A
RANI Rani Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AADI Aadi Bioscience	N/A	4.89	4.54
CALC CalciMedica	1.39	5.45	5.45
GLYC GlycoMimetics	N/A	1.92	1.92
RANI Rani Therapeutics	2.75	0.54	0.54

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AADI Aadi Bioscience	52.08%
CALC CalciMedica	N/A
GLYC GlycoMimetics	75.19%
RANI Rani Therapeutics	30.19%

Insider Ownership

Company	Insider Ownership
AADI Aadi Bioscience	37.30%
CALC CalciMedica	41.55%
GLYC GlycoMimetics	8.70%
RANI Rani Therapeutics	45.08%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AADI Aadi Bioscience	40	24.70 million	15.49 million	Optionable
CALC CalciMedica	30	13.97 million	8.17 million	No Data
GLYC GlycoMimetics	50	64.53 million	58.90 million	Optionable
RANI Rani Therapeutics	110	71.87 million	39.47 million	Optionable

GLYC, AADI, RANI, and CALC Headlines

Recent News About These Companies

Wall Street Zen Upgrades Rani Therapeutics (NASDAQ:RANI) to Hold

August 18, 2025 | americanbankingnews.com

Rani Therapeutics Reports Q2 2025 Financial Results

August 13, 2025 | msn.com

RANI: Second Quarter Financial Results

August 12, 2025 | finance.yahoo.com

Rani (RANI) Q2 Net Loss Improves 16%

August 9, 2025 | theglobeandmail.com

Rani Therapeutics Reports Second Quarter 2025 Financial Results; Provides Corporate Update

August 7, 2025 | globenewswire.com

Rani Therapeutics Holdings, Inc. (RANI) - Yahoo Finance

July 18, 2025 | finance.yahoo.com

Rani Therapeutics Shares Drop Sharply Following $3 Million Direct Offering Announcement

July 15, 2025 | msn.com

Rani Therapeutics Holdings, Inc. Announces Pricing of $3.0 Million Registered Direct Offering

July 15, 2025 | globenewswire.com

Rani Therapeutics Shares Surge After ENDO 2025 Presentation Announcement

July 14, 2025 | msn.com

Rani Therapeutics and ProGen Announce Late Breaking Presentation at ENDO 2025 Demonstrating ...

July 14, 2025 | bakersfield.comB

Rani Therapeutics to Present Preclinical Data on RaniPill® Capsule at ENDO 2025 Conference

July 14, 2025 | quiverquant.comQ

Rani Therapeutics and ProGen Announce Late Breaking Presentation at ENDO 2025 Demonstrating Bioequivalence of Novel, Bispecific GLP-1/GLP-2 Receptor Agonist Delivered Orally via RaniPill Compared to Subcutaneous Delivery

July 14, 2025 | globenewswire.com

Genelux Appoints Groen as General Counsel From Rani Therapeutics

July 8, 2025 | news.bloomberglaw.comN

Rani Therapeutics announces annual meeting results

May 30, 2025 | investing.com

Rani Therapeutics strikes deal to issue new warrants

May 21, 2025 | uk.investing.com

RANI: 1Q:25 Financial Results

May 20, 2025 | finance.yahoo.com

Rani Therapeutics Announces Research Agreement with Chugai

May 19, 2025 | globenewswire.com

Rani Therapeutics Reports First Quarter 2025 Financial Results; Provides Corporate Update

May 13, 2025 | globenewswire.com

Rani Therapeutics Faces Nasdaq Compliance Challenge

May 6, 2025 | tipranks.com

Stifel Nicolaus Remains a Buy on Trevi Therapeutics (TRVI)

April 23, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

GLYC, AADI, RANI, and CALC Company Descriptions

Aadi Bioscience NASDAQ:AADI

$1.65 0.00 (0.00%)

As of 08/21/2025

Aadi Bioscience, Inc., a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa. The company is also involved in evaluating FYARRO in cancers, including indications targeting specific genomic alterations that activate the mTOR pathway. Aadi Bioscience, Inc. was incorporated in 2007 and is headquartered in Pacific Palisades, California.

CalciMedica NASDAQ:CALC

$2.78 -0.01 (-0.36%)

Closing price 08/22/2025 03:58 PM Eastern

Extended Trading

$2.80 +0.02 (+0.72%)

As of 08/22/2025 07:46 PM Eastern

CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. It also develops CM6336, an oral CRAC channel inhibitors for chronic inflammatory indications; and Auxora, for the treatment of acute ulcerative colitis and allergic asthma. The company is based in La Jolla, California.

GlycoMimetics NASDAQ:GLYC

GlycoMimetics, Inc., a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and GMI-2093, a galectin-3 carbohydrate-binding protein. In addition, its portfolio comprises GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of osteosarcoma. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.

Rani Therapeutics NASDAQ:RANI

$0.62 +0.08 (+13.82%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$0.59 -0.03 (-5.51%)

As of 08/22/2025 07:11 PM Eastern

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time